Mesoblast Limited LWBA.F Stock
Mesoblast Limited Price Chart
Mesoblast Limited LWBA.F Financial and Trading Overview
Mesoblast Limited stock price | 0.94 EUR |
Previous Close | 3.34 EUR |
Open | 3.3 EUR |
Bid | 3.3 EUR x 90000 |
Ask | 3.42 EUR x 90000 |
Day's Range | 3.3 - 3.3 EUR |
52 Week Range | 2.12 - 4.2 EUR |
Volume | 4 EUR |
Avg. Volume | 17 EUR |
Market Cap | 537.02M EUR |
Beta (5Y Monthly) | 2.434099 |
PE Ratio (TTM) | 0.29385576 |
EPS (TTM) | 0 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 11.7 EUR |
LWBA.F Valuation Measures
Enterprise Value | 557.84M EUR |
Trailing P/E | 0.29385576 |
Forward P/E | -11.379311 |
PEG Ratio (5 yr expected) | -0.09 |
Price/Sales (ttm) | 70.79035 |
Price/Book (mrq) | 1.0076336 |
Enterprise Value/Revenue | 73.536 |
Enterprise Value/EBITDA | -8.268 |
Trading Information
Mesoblast Limited Stock Price History
Beta (5Y Monthly) | 2.434099 |
52-Week Change | 45.21% |
S&P500 52-Week Change | 20.43% |
52 Week High | 4.2 EUR |
52 Week Low | 2.12 EUR |
50-Day Moving Average | 3.12 EUR |
200-Day Moving Average | 3.06 EUR |
LWBA.F Share Statistics
Avg. Volume (3 month) | 17 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 162.73M |
Float | 122.49M |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 1.94% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | June 30, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | June 30, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -922.99% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -6.56% |
Return on Equity (ttm) | -16.29% |
Income Statement
Revenue (ttm) | 7.59M EUR |
Revenue Per Share (ttm) | 0.06 EUR |
Quarterly Revenue Growth (yoy) | -3.59% |
Gross Profit (ttm) | -53361000 EUR |
EBITDA | -67471000 EUR |
Net Income Avi to Common (ttm) | -81425000 EUR |
Diluted EPS (ttm) | 11.23 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 48.8M EUR |
Total Cash Per Share (mrq) | 0.33 EUR |
Total Debt (mrq) | 114.61M EUR |
Total Debt/Equity (mrq) | 23.77 EUR |
Current Ratio (mrq) | 1.138 |
Book Value Per Share (mrq) | 3.275 |
Cash Flow Statement
Operating Cash Flow (ttm) | -60885000 EUR |
Levered Free Cash Flow (ttm) | -50345700 EUR |
Profile of Mesoblast Limited
Country | Germany |
State | VIC |
City | Melbourne |
Address | 55 Collins Street |
ZIP | 3000 |
Phone | 61 3 9639 6036 |
Website | https://www.mesoblast.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 77 |
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Q&A For Mesoblast Limited Stock
What is a current LWBA.F stock price?
Mesoblast Limited LWBA.F stock price today per share is 0.94 EUR.
How to purchase Mesoblast Limited stock?
You can buy LWBA.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Mesoblast Limited?
The stock symbol or ticker of Mesoblast Limited is LWBA.F.
Which industry does the Mesoblast Limited company belong to?
The Mesoblast Limited industry is Biotechnology.
How many shares does Mesoblast Limited have in circulation?
The max supply of Mesoblast Limited shares is 171.63M.
What is Mesoblast Limited Price to Earnings Ratio (PE Ratio)?
Mesoblast Limited PE Ratio is 0.00000000 now.
What was Mesoblast Limited earnings per share over the trailing 12 months (TTM)?
Mesoblast Limited EPS is 0 EUR over the trailing 12 months.
Which sector does the Mesoblast Limited company belong to?
The Mesoblast Limited sector is Healthcare.